Table 1 Patients features and risk factors/laboratory values associated with mortality.

Sex

M

M

M

M

F

F

Age

28

46

60

55

74

34

Diagnosis

AML

AML

AML

AML

MDS

AML

Donor

MMRD

MUD

MUD

MMRD

MUD

MUD

Time post HSCT

12 m

43 m

36 m

40 m

8 y

14 y

T/B-cell recovery

+/+

+/+

+/+

+/−

+/+

+/+

IgG/IgA/IgM recovery

+/−/+

+/+/+

+/+/+

+/−/+

+/+/+

+/+/+

Chronic GvHD

No

Yes

Yes

Yes

Yes

Yes

Chronic GvHD severity and site at COVID-19 onset

n.a.

Severe

Joint and Fascia

Resolved

Mild

Skin

Mild

Eyes

Severe

Skin, Mouth, Eyes, Joint and Fascia

Systemic IST

No

Imatinib/MTX

No

Ruxolitinib

No

Ruxolitinib

Symptoms

Anosmia Ageusia

Fever

Headache

Fever

Cough

Fever

Cough

Fever

Cough

Fever

Myalgia

MEWS

0

2

2

3

5

3

PPSv2

100%

80%

80%

40%

40%

50%

CIRS

4

9

6

13

10

15

PSI

n.a.

n.a.

n.a.

III

IV

III

APACHE

n.a.

n.a.

n.a.

13

16

11

Outcome

 (n*; n**)

Resolved

(280; n.a.)

Resolved

(305; n.a.)

Resolved

(285; n.a.)

Discharged

Resolved

(286; 37)

Discharged

Resolved

(278; 13)

Discharged

Resolved

(291; 8)

 Age ≥ 60 y

No

No

Yes

No

Yes

No

 Male gender

Yes

Yes

Yes

Yes

No

No

 Hypertension

No

No

Yes

Yes

No

Yes

 Cardiovascular disease

No

No

No

Yes

No

No

 Diabetes

No

No

No

No

No

No

 Chronic lung disease

No

Yes

No

No

Yes

No

 Elevated LDH (>220 U/L)

n.a.

n.a.

n.a.

404

303

322

 Elevated CRP (>6 mg/L)

n.a.

n.a.

n.a.

153

248

99

 Elevated D-dimer (>0.5 mcg/L)

n.a.

n.a.

n.a.

No

1.6

No

 Elevated PT inr (ratio > 1.18)

n.a.

n.a.

n.a.

No

0.93

No

 Platelets <100 × 10⁹/L

n.a.

n.a.

n.a.

209

141

266

 Lymphocytes <0.8 × 10⁹/L

n.a.

n.a.

n.a.

0.4

1.9

0.9

 Ground glass opacities

n.a.

n.a.

n.a.

Yes

No

Yes

 Bilateral pneumonia

n.a.

n.a.

n.a.

Yes

Yes

Yes

 Pao₂/Fio₂ < 300 mmHg

n.a.

n.a.

n.a.

No

Yes

No